清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy–Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer

医学 乳腺癌 心脏毒性 内科学 生物标志物 癌症 蒽环类 肿瘤科 无症状的 射血分数 曲妥珠单抗 前瞻性队列研究 肌钙蛋白 心力衰竭 化疗 心脏病学 心肌梗塞 生物化学 化学
作者
Anthony F. Yu,Zachary Moore,Chaya S. Moskowitz,Jennifer E. Liu,Chau T. Dang,Lakshmi Ramanathan,Kevin C. Oeffinger,Richard M. Steingart,Adam Schmitt
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:8 (7): 697-697 被引量:2
标识
DOI:10.1001/jamacardio.2023.1229
摘要

Importance Cancer therapy–related cardiac dysfunction (CTRCD) is a potentially serious cardiotoxicity of treatments for ERBB2 -positive breast cancer (formerly HER2 ). Identifying early biomarkers of cardiotoxicity could facilitate an individualized approach to cardiac surveillance and early pharmacologic intervention. Circulating cell-free DNA (cfDNA) of cardiomyocyte origin is present during acute cardiac injury but has not been established as a biomarker of CTRCD. Objective To determine whether circulating cardiomyocyte cfDNA is associated with CTRCD in patients with ERBB2 -positive breast cancer treated with anthracyclines and ERBB2 -targeted therapy. Design, Setting, and Participants A prospective cohort of 80 patients with ERBB2 -positive breast cancer enrolled at an academic cancer center between July 2014 and April 2016 underwent echocardiography and blood collection at baseline, after receiving anthracyclines, and at 3 months and 6 months of ERBB2 -targeted therapy. Participants were treated with doxorubicin-based chemotherapy followed by trastuzumab (+/− pertuzumab). The current biomarker study includes participants with sufficient biospecimen available for analysis after anthracycline therapy. Circulating cardiomyocyte-specific cfDNA was quantified by a methylation-specific droplet digital polymerase chain reaction assay. Data for this biomarker study were collected and analyzed from June 2021 through April 2022. Main Outcomes and Measures The outcome of interest was 1-year CTRCD, defined by symptomatic heart failure or an asymptomatic decline in left ventricular ejection fraction (≥10% from baseline to less than lower limit of normal or ≥16%). Values for cardiomyocyte cfDNA and high-sensitivity cardiac troponin I (hs-cTnI) measured after patients completed treatment with anthracyclines were compared between patients who later developed CTRCD vs patients who did not using the Wilcoxon rank sum test, and the association of post-anthracycline cardiomyocyte cfDNA level with CTRCD was estimated using logistic regression. Results Of 71 patients included in this study, median (IQR) age was 50 (44-58) years, all were treated with dose-dense doxorubicin, and 48 patients underwent breast radiotherapy. Ten of 71 patients (14%) in this analysis developed CTRCD. The level of cardiomyocyte cfDNA at the post-anthracycline time point was higher in patients who subsequently developed CTRCD (median, 30.5 copies/mL; IQR, 24-46) than those who did not (median, 7 copies/mL; IQR, 2-22; P = .004). Higher cardiomyocyte cfDNA level after completion of anthracycline chemotherapy was associated with risk of CTRCD (hazard ratio, 1.02 per 1-copy/mL increase; 95% CI, 1.00-1.03; P = .046). Conclusions and Relevance This study found that higher cardiomyocyte cfDNA level after completion of anthracycline chemotherapy was associated with risk of CTRCD. Cardiomyocyte cfDNA quantification shows promise as a predictive biomarker to refine risk stratification for CTRCD among patients with breast cancer receiving cardiotoxic cancer therapy, and its use warrants further validation. Trial Registration ClinicalTrials.gov Identifier: NCT02177175
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小婷君完成签到 ,获得积分10
27秒前
呆呆的猕猴桃完成签到 ,获得积分10
29秒前
35秒前
BlueCai发布了新的文献求助10
41秒前
48秒前
键盘车神完成签到 ,获得积分10
48秒前
li8888lili8888完成签到 ,获得积分10
48秒前
CodeCraft应助东东西西采纳,获得10
54秒前
1分钟前
1分钟前
东东西西发布了新的文献求助10
1分钟前
爆米花应助goneaaron采纳,获得10
1分钟前
刘天虎研通完成签到 ,获得积分10
1分钟前
yi完成签到,获得积分10
1分钟前
小和发布了新的文献求助10
2分钟前
游01完成签到 ,获得积分10
2分钟前
a46539749完成签到 ,获得积分10
2分钟前
在水一方应助ju龙哥采纳,获得10
4分钟前
4分钟前
ju龙哥发布了新的文献求助10
4分钟前
传奇3应助科研通管家采纳,获得10
4分钟前
yulong完成签到,获得积分10
4分钟前
哆啦A梦完成签到 ,获得积分10
5分钟前
哆啦A梦完成签到 ,获得积分10
5分钟前
斯文败类应助linlin采纳,获得10
5分钟前
会飞的猪完成签到 ,获得积分20
5分钟前
linlin完成签到,获得积分10
6分钟前
小强完成签到 ,获得积分10
7分钟前
linlin发布了新的文献求助10
7分钟前
8分钟前
来自三百完成签到 ,获得积分10
8分钟前
8分钟前
周周南完成签到 ,获得积分10
8分钟前
世隐完成签到,获得积分10
9分钟前
粗暴的问寒完成签到,获得积分10
9分钟前
oracl完成签到 ,获得积分10
9分钟前
BlueCai发布了新的文献求助10
9分钟前
BlueCai完成签到,获得积分10
10分钟前
10分钟前
10分钟前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 800
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
Active principle of croton oil. VII. Phorbol 500
The three stars each: the Astrolabes and related texts 500
Revolutions 400
Diffusion in Solids: Key Topics in Materials Science and Engineering 400
Phase Diagrams: Key Topics in Materials Science and Engineering 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2445549
求助须知:如何正确求助?哪些是违规求助? 2121174
关于积分的说明 5392727
捐赠科研通 1849557
什么是DOI,文献DOI怎么找? 920244
版权声明 562093
科研通“疑难数据库(出版商)”最低求助积分说明 492192